
Early Talk Therapy After Stroke Tied to Better Psych Outcome
Psychological therapy was associated with significantly reduced symptoms of depression and anxiety among patients with a history of stroke, with greater benefits in those who initiated talk therapy within 6 months of the stroke compared to those who began treatment later, new research showed.
METHODOLOGY:
Researchers analyzed data from more than 7000 adults with a hospital diagnosis of stroke. All had undergone at least two sessions of poststroke psychological treatment through the National Health Service Talking Therapies program for anxiety and depression in England between 2012 and 2019.
Primary outcomes included 'reliable improvement,' defined as a 6-point or greater reduction on the 9-item Patient Health Questionnaire (PHQ-9) or a 4-point or greater reduction on the 7-item Generalized Anxiety Disorder scale (GAD-7); 'reliable recovery,' which included improvement along with scores below 10 on the PHQ-9 and scores below 8 on the GAD-7; and 'reliable deterioration,' defined as at least a 6-point increase on PHQ-9 or at least a 4-point increase on GAD-7.
Secondary outcomes included pre- to posttreatment score changes on the PHQ-9 and GAD-7.
TAKEAWAY:
After undergoing talk therapy, 71% of patients with a history of stroke and baseline depression or anxiety symptoms had reliable improvement in psychiatric symptoms, and 49% had reliable recovery, while only 7% had reliable deterioration.
After treatment, mean PHQ-9 and GAD-7 scores decreased by 6.5 and 5.5 points, respectively, indicating moderate reductions in depression symptoms and large reductions in anxiety symptoms.
Analysis adjusted for demographics and other covariates showed that patients who initiated psychological services 12 months or more after stroke had 20% lower odds of reliable recovery compared to those who initiated treatment within 6 months of stroke.
Compared with a matched sample of individuals who never had a stroke, those with a history of stroke were less likely to reliably recover (odds ratio [OR], 0.9; P < .001) and more likely to reliably deteriorate (OR, 1.2; P = .04), but these differences disappeared after adjusting for physical comorbidities.
IN PRACTICE:
The study 'strongly supports the effectiveness of primary care psychological therapy as a first-line treatment for common mental health disorders after a stroke,' the researchers wrote.
'It is essential for general practitioners and other clinicians working with stroke survivors to screen for depression and anxiety symptoms and refer patients for psychological therapy as early as possible,' the lead investigator said in a press release.
SOURCE:
The study, led by Jae Won Suh, University College London, London, England, was published online on June 5 in Nature Mental Health .
LIMITATIONS:
The sample may not have represented all survivors of stroke, especially those with severe impairments or those from underrepresented ethnic backgrounds. The study also lacked detailed data on stroke severity, cognitive or sensory deficits, and prestroke mental health status, as well as information on whether depression or anxiety began before or after the stroke. Information on lifestyle factors and the burden of comorbidities was also limited.
DISCLOSURES:
This study was funded by the Alzheimer's Society. Some investigators reported having unrelated consulting roles and funding from various organizations. Full details are provided in the original article.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fast Company
an hour ago
- Fast Company
Ear wax may hold the key to early Parkinson's diagnosis
An unlikely body byproduct may be able to help doctors diagnose Parkinson's Disease early. According to a new Chinese study, which was published in Analytical Chemistry, ear canal secretion, or ear wax, contain chemical compounds which can be telltale signs of Parkinson's. During the study, researchers examined ear canal secretions from 209 people. About half (108 of the participants) had Parkinson's. In their examinations, scientists were able to identify four volatile organic compounds (VOC) that were notably different in those with the disease. Those compounds, or biomarkers, were ethylbenzene, 4-ethyltoluene, pentanal, and 2-pentadecyl-1,3-dioxolane. The scientists then trained an artificial intelligence olfactory (AIO) system on the biomarker data. And once training was complete, the AIO system was able to successfully determine which patients had Parkinson's and which did not. The system was accurate 94% of the time. Currently, Parkinson's is a tough disease to diagnose. According to Mayo Clinic, it requires expensive imaging, neurological tests, blood tests, genetic testing, and more. And often, a diagnosis is still often not conclusive. Likewise, treatment is a work-in-progress, with current therapies aimed at slowing progression rather than curing it. Therefore, ear wax testing could be a breakthrough first-step screening tool that's inexpensive, noninvasive, and accessible. The researchers who worked on the study say the findings are a major step in Parkinson's early detection, which currently, doesn't exist, but that more research is needed. 'This method is a small-scale single-center experiment in China,' study coauthor Hao Dong said in a press release. Hoa Dong continued, 'The next step is to conduct further research at different stages of the disease, in multiple research centers and among multiple ethnic groups, in order to determine whether this method has greater practical application value.'
Yahoo
an hour ago
- Yahoo
Major Investment to Transform Mental Health Research
OTTAWA, ON, June 19, 2025 /CNW/ - Brain Canada is proud to announce its support for the development of the Brain Imaging Centre Advanced Multi-modal neuroimaging Platform for Psychiatry (BIC-AMPP) at The Royal Ottawa Health Care Group's BIC. Through its 2024 Platform Support Grants (PSG) program, Brain Canada is partnering with The Royal to invest $1.9 million in this groundbreaking initiative, which will integrate multiple brain imaging modalities to revolutionize mental health research. Led by Dr. Georg Northoff of the University of Ottawa's Institute of Mental Health Research (IMHR), the BIC-AMPP project brings together experts in MRI, PET, and EEG imaging to unlock the complex biochemical, structural, and functional changes associated with mental illness. This rare and technically advanced platform will allow researchers to simultaneously capture a more thorough and integrated picture of the brain, laying the groundwork for improved diagnostics and personalized treatments. "This investment represents a step-change in the capabilities of our team and our infrastructure, positioning Canada at the forefront of brain imaging research for mental health," said Dr. Florence Dzierszinski, President and CEO of the IMHR and vice-president of research at The Royal. "Simultaneous tri-modal imaging is only being actively pursued in two other centres in the world, yet offers endless possibilities with the right technology and skills." "This platform will enable us to link brain structure, chemistry, and function in real time," said Katie Dinelle, Administrative Director of The Royal's Clinical Brain Research Centre. "It will give us a more complete picture of mental illness and open new doors for discovery." "Mental health research has long been limited by our inability to fully understand how the brain's structure, chemistry, and function interact," said Dr. Georg Northoff, lead Principal Investigator for the BIC-AMPP. "By integrating multiple imaging modalities in a single platform, we can finally start to connect the dots. This will help us move beyond fragmented insights toward a more holistic understanding of mental illness—one that can inform better, more personalized treatments." The BIC-AMPP platform is designed to foster collaboration among scientists and provide unprecedented access to simultaneous multi-modal imaging, positioning The Royal as a hub for innovation and knowledge mobilization. Supported by expert scientific staff and a secure, open-access data-sharing infrastructure, the platform will accelerate discoveries that improve mental health care in Canada and beyond. Dr. Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of this initiative: "The BIC-AMPP represents a major leap forward in our ability to understand mental illness and develop personalized treatments. Brain Canada is proud to support this visionary platform, which underlines Canada's position as a global leader in brain imaging research." Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. "Research and innovation deepen our understanding, unlock new treatments, and improve quality of life for people affected by mental illness," said the Honourable Marjorie Michel, Minister of Health. "Through the Canada Brain Research Fund, the Government of Canada is pleased to support this initiative, bringing together experts from different fields to accelerate discoveries that will improve mental health care for Canadians." Over the coming weeks, Brain Canada will unveil the full list of 14 research platforms selected to receive PSG funding. The total investment of $36.8 million represents a major step forward in Canada's ability to support cutting-edge brain research and improve outcomes for people living with brain-disorders. For more information, please visit The Royal is one of Canada's foremost mental health care, teaching, and research hospitals and is home to the Royal Ottawa Mental Health Centre, the Brockville Mental Health Centre, the University of Ottawa Institute of Mental Health and the Royal Ottawa Foundation for Mental Health. Our mission is to transform the lives of people living with complex mental illness and addictions. Learn more about The Royal, our services, and our impact. SOURCE Brain Canada View original content to download multimedia:
Yahoo
an hour ago
- Yahoo
How your ear wax could tell you if you have Parkinson's disease, according to experts
Could your ear wax tell you if you have Parkinson's disease? Some 90,000 people are diagnosed with the degenerative neurological condition in the U.S. each year, and annual deaths have surged in recent decades to tens of thousands. Now, researchers at the American Chemical Society claim they have developed a new system that could help catch the disease at an early stage. The identifier is in the odor of ear wax's main ingredient, known as sebum. The oily substance is produced by the body to lubricate and protect the skin. Sebum from people with Parkinson's may have a characteristic and musky smell because the volatile organic compounds released by sebum are altered by disease progression. This association has been identified in previous research. To identify the compounds released by sebum in people with the disease, the researchers swabbed the ear canals of 209 participants, more than half of which were diagnosed with the condition. Then, they analyzed what was collected using gas chromatography and mass spectrometry techniques. Four of the volatile organic compounds they found in people with Parkinson's were different than people without it. Those include ethylbenzene, 4-ethyltoluene, pentanal, and 2-pentadecyl-1,3-dioxolane. The researchers said they are potential biomarkers for Parkinson's. Using these findings, published this week in the journal Analytical Chemistry, they were able to develop a system that inexpensively screens for Parkinson's. They trained an artificial intelligence olfactory system - a robotic model that can mimic how we smell - with their ear wax compound data. Using the model, they found it was able to categorize samples with and without Parkinson's with 94 percent accuracy. Some 1.1 million Americans are living with Parkinson's right now. Because most treatments for Parkinson's only slow the progression of disease, catching it early is critical. Current testing is also costly, and can be subjective. This AI system, the researchers say, could be used as a first-line screening tool for early detection. 'This method is a small-scale single-center experiment in China,' explained author Hao Dong. 'The next step is to conduct further research at different stages of the disease, in multiple research centers and among multiple ethnic groups, in order to determine whether this method has greater practical application value.'